Hager_2001_Arch.Gerontol.Geriatr_32_275

Reference

Title : Alpha-lipoic acid as a new treatment option for Azheimer type dementia - Hager_2001_Arch.Gerontol.Geriatr_32_275
Author(s) : Hager K , Marahrens A , Kenklies M , Riederer P , Munch G
Ref : Arch Gerontol Geriatr , 32 :275 , 2001
Abstract :

Oxidative stress and energy depletion are characteristic biochemical hallmarks of Alzheimer's disease (AD), thus antioxidants with positive effects on glucose metabolism such as thioctic (alpha-lipoic) acid should exert positive effects in these patients. Therefore, 600 mg alpha-lipoic acid was given daily to nine patients with AD and related dementias (receiving a standard treatment with acetylcholinesterase inhibitors) in an open study over an observation period of, on avarage, 337+/-80 days. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (mini-mental state examination: MMSE and AD assessment scale, cognitive subscale: ADAScog). Despite the fact that this study was small and not randomized, this is the first indication that treatment with alpha-lipoic acid might be a successful 'neuroprotective' therapy option for AD and related dementias.

PubMedSearch : Hager_2001_Arch.Gerontol.Geriatr_32_275
PubMedID: 11395173

Related information

Citations formats

Hager K, Marahrens A, Kenklies M, Riederer P, Munch G (2001)
Alpha-lipoic acid as a new treatment option for Azheimer type dementia
Arch Gerontol Geriatr 32 :275

Hager K, Marahrens A, Kenklies M, Riederer P, Munch G (2001)
Arch Gerontol Geriatr 32 :275